Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma
Clinical trial NCT07572123 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07572123
- Sponsor
- National Cancer Institute (NCI)
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-12-04
- Primary completion
- 2029-03-31
- Enrollment
- 374
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.